Dalpicilib-Enhanced vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer

This study aims to conduct a randomized controlled clinical trial to compare the efficacy and safety of dalpicilib combined with endocrine therapy versus standard endocrine therapy in ER-positive, HER2-negative, lymph node-negative patients with risk factors, in order to further optimize the regimen for adjuvant endocrine therapy in breast cancer.

Trial Details

NCT ID

NCT06637150

Phase

PHASE3

Sponsor

Fudan University

Status

RECRUITING

Cancer Type

Breast Cancer

Interventions

Dalpicilib
endocrine therapy

Locations (sample)

Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

Women aged 18-70 years
ECOG score of 0-1
Histologically confirmed unilateral invasive cancer (regardless of pathology type)
No macroscopic or microscopic tumor residue after surgical resection

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →